Odyssey Therapeutics
Odyssey Therapeutics develops machine-learning-designed therapies for people with autoimmune diseases. It applies computational immunology and modern machine learning to design personalized therapeutics tailored to individual physiology and genetic background. The company operates as a biotech and computational immunology firm leveraging ML, immunology, and genomics technologies. Odyssey targets the underserved autoimmune market and aims to advance tailored treatment options for patients.
Odyssey Therapeutics
Odyssey Therapeutics develops machine-learning-designed therapies for people with autoimmune diseases. It applies computational immunology and modern machine learning to design personalized therapeutics tailored to individual physiology and genetic background. The company operates as a biotech and computational immunology firm leveraging ML, immunology, and genomics technologies. Odyssey targets the underserved autoimmune market and aims to advance tailored treatment options for patients.
TL;DR
Focus: Machine-learning and computational immunology to design therapeutics for autoimmune disease and oncology
Founded: 2018
Headquarters (listed): Boston / Cambridge, MA and San Francisco references in records
Notable investors: SR One; OrbiMed; HBM Healthcare; General Catalyst (among others)
Funding (reported multiples): Multiple large venture rounds beginning in 2021 (Series A–C reported by sources)
Company Overview
Problem Domain
Autoimmune diseases and oncology; precision immunomodulation
Founded
2018
Industry
Biotechnology
Funding Track Record
218000000
Reported Series A announced Dec 7, 2021 (sources list SR One and OrbiMed as lead investors).
168000000
Reported Series B Oct 2022 (sources list General Catalyst as lead on Series B).
101000000
Reported Series C Dec 2023 per sourced company listings.
Investor Signal
“SR One; OrbiMed; HBM Healthcare; Woodline Partners; Foresite Capital; General Catalyst; Logos Capital”